Clinical Trials Logo

Behçet Disease clinical trials

View clinical trials related to Behçet Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06386744 Not yet recruiting - Behçet Disease Clinical Trials

Dusquetide for the Treatment of Behcet's Disease

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks.

NCT ID: NCT05715294 Not yet recruiting - Sleep Quality Clinical Trials

The Effect of Music on Sleep Quality in Behçet's Patients

Start date: January 30, 2023
Phase: N/A
Study type: Interventional

The aim of this study was to evaluate effect of music on sleep quality in patients with Behçet's disease. The population of the study consists of behçet patients who applied to the Rheumatology outpatient clinic of Medical Faculty Hospital, who met the research criteria and agreed to participate in the study. The study will conduct in a randomized controlled experimental design with two groups. The sample of the study will be 50 behçet patients the music practice group (25) and the control group (25). The research will be carried out between December 2022 and December 2023. In this study, data will with collect Descriptive Information Form, Behçet's Syndrome Activity Scale (BSAS) and Richard-Campbell Sleep Scale (RCUI).

NCT ID: NCT05128357 Not yet recruiting - Behçet Disease Clinical Trials

IMPACT_BD (IMProving AdherenCe to Treatment in Behçet's Disease)

IMPACT_BD
Start date: November 16, 2021
Phase:
Study type: Observational

Behçet's disease (BD) is an autoimmune, rare, and severe multisystemic inflammatory disease characterized by recurrent oral aphthous ulcers, genital ulcers, skin lesions, and both anterior and posterior uveitis; articular, vascular, gastroenteric and neurological involvement may also occur. The multi-organ involvement and the wide range of clinical spectrum make the diagnosis of BD challenging. Adherence has been defined as the "extent to which a person's behavior (in terms of taking medications, following diets, or executing other lifestyle changes) corresponds with agreed recommendations from a health care provider". The lack of medication adherence leads to poorer health outcomes for the patients, which affect quality of life, generate economic loss for the healthcare system and trigger uncertainty for the healthcare prescribers in dealing with the disease treatment. This challenge is particularly important in BD. The present study is therefore aimed at exploring the main reasons for low- or non-adherence to treatments in BD and to create a specific tool able to catch and monitor the reasons for low- or non-adherence in BD over time. Objectives - to explore the unmet needs in treatment adherence - to create a toll aimed at identifying and monitoring the reasons of low treatment adherence - to plan specific actions aimed at improving treatment adherence in BD

NCT ID: NCT04186559 Not yet recruiting - Behcet Syndrome Clinical Trials

Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

Start date: February 2024
Phase: Phase 2
Study type: Interventional

Behçet's Disease (BD) is a complex, chronic, relapsing, multi-system inflammatory disorder that is characterized by oral ulcers, genital ulcers in addition to ocular and skin symptoms. Genital ulcers are the second most common symptom of BD and occur in 57-93% of BD patients. The genital ulcers of BD clearly cause considerable morbidity for those affected. This will be one of the first trials of a topical product designed for accelerated healing of BD genital ulcers. There is no cure or FDA-approved therapies for BD genital ulcers and the treatment of recurrent genital ulcers that are associated with BD is palliative. Recent study evaluating the effect of topical PTX on BD oral ulcers suggests that topical pentoxifylline (PTX) might have an immediate impact on BD oral ulcer healing leading to accelerated ulcer clearance, which results in lower daily ulcer numbers for the patients along with reduced pain scores. Investigators hypothesize that application of topical PTX will accelerate the healing of BD genital ulcers in a similar clinically meaningful way, and further hypothesize that topical PTX can become a valuable adjunct to any other systemic therapy for BD.

NCT ID: NCT04126850 Not yet recruiting - Behçet Disease Clinical Trials

Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease

Start date: November 1, 2019
Phase:
Study type: Observational

This study aimed to discover the composition on the microbiome in several sites of the human body; and to find out the difference in microbiome composition on ocular fluid, blood, and feces before and after therapy in uveitis patient with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis

NCT ID: NCT04105439 Not yet recruiting - Behçet Disease Clinical Trials

Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .

Start date: July 1, 2021
Phase:
Study type: Observational

The purpose of the study is to determine whether plasma levels of the soluble urokinase plasminogen activator(suPAR) can serve as a blood-based biomarker for diagnosis of Behçet's disease and its correlation with disease activity.